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Visceral leishmaniasis is a neglected parasitic disease with no vaccine available and its
pharmacological treatment is reduced to a limited number of unsafe drugs. The scarce read-
iness of new antileishmanial drugs is even more alarming when relapses appear or the
occurrence of hard-to-treat resistant strains is detected. In addition, there is a gap between
the initial and late stages of drug development, which greatly delays the selection of leads
for subsequent studies.
Methodology/Principal findings
In order to address these issues, we have generated a red-shifted luminescent Leishmania
infantum strain that enables long-term monitoring of parasite burden in individual animals
with an in vivo limit of detection of 106 intracellular amastigotes 48 h postinfection. For this
purpose, we have injected intravenously different infective doses (104—5x108) of metacyclic
parasites in susceptible mouse models and the disease was monitored from initial times to
21 weeks postinfection. The emission of light from the target organs demonstrated the
sequential parasite colonization of liver, spleen and bone marrow. When miltefosine was
used as proof-of-concept, spleen weight parasite burden and bioluminescence values
decreased significantly.
Conclusions
In vivo bioimaging using a red-shifted modified Leishmania infantum strain allows the
appraisal of acute and chronic stage of infection, being a powerful tool for accelerating drug
development against visceral leishmaniasis during both stages and helping to bridge the
gap between early discovery process and subsequent drug development.
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Author summary
Visceral leishmaniasis is a neglected disease that poses a significant threat to impoverished
human populations of low-income countries. Due to the unavailability of vaccines, phar-
macological treatment is the only approach to control the disease that otherwise can be
lethal. To date, drug management in endemic regions is based on combinations of a hand-
ful of mostly unsafe drugs, where the emergence of resistant strains is an additional prob-
lem. To accelerate the discovery of new drug entities, several gaps from the early discovery
of a compound to its public use, should be filled. One of these gaps is the need of a rapid
go/no-go testing system for compounds based on robust preclinical models. Here, we pro-
pose a new long-term model of murine visceral leishmaniasis using in vivo bioluminescent
imaging. For this purpose, a red-shifted bioluminescent Leishmania infantum strain was
engineered. This strain has allowed the appraisal of the disease in individual animals and
the monitoring of parasite colonization in liver, spleen and bone marrow. As proof of con-
cept of this platform, mice were infected with the transgenic L. infantum strain treated
with a standard schedule of miltefosine, the only oral drug available against Leishmania
parasites. Bioluminescence and parasite load in the target organs were compared showing
a good correlation. Our findings provide a robust and reproducible tool for drug discov-
ery in a chronic model of murine visceral leishmaniasis.
Introduction
Leishmaniasis is a complex of neglected parasitic diseases affecting the poorest people in 98
countries, particularly those with weak or non-existent health systems. [1]. There are at least
three different forms of clinical presentations; cutaneous, mucocutaneous and visceral leish-
maniasis, the latter being fatal if left untreated [2]. Visceral leishmaniasis (VL) is estimated to
produce 300.000 new cases and between 20.000–40.000 deaths every year. Most of the cases
are localized in three geographical regions; South Asia and East Africa where the disease is
caused by Leishmania donovani and the transmission is mostly anthroponotic. By its part, in
Brazil, where the disease is produced by L. infantum chagasi, the transmission is zoonotic and
occurs mainly from infected dogs [3].
Nowadays, therapeutic or prophylactic human vaccines are still lacking, and the cure of
patients is based on chemotherapy [4, 5]. Treatment of VL was mainly based on painful intra-
muscular injections of pentavalent antimonials, such as sodium stibogluconate (SSG). SSG has
been the first-line antileishmanial drug in India, although its clinical efficacy in some areas of
North Bihar State has gradually declined, due to the emergence of fully resistant L. donovani
strains. SSG is being substituted by liposomal amphotericin B (AmBisome) as first-line treat-
ment, despite slow intravenous administration of the drug is needed [6–8]. In East Africa, SSG
was the first-line regimen for decades, but due to its toxicity and following WHO recommen-
dations in 2010, SSG + paromomycin combination therapy became the treatment of choice
[9]. However, the administration of this drug combination is painful and requires patient hos-
pitalization, and therefore, more friendly alternatives were implemented. These include single
dose of AmBisome plus 10 consecutive days of SSG, single dose of AmBisome plus 10 days of
miltefosine or miltefosine alone for 28 days. However, none of these combinations improved
the results of the treatment of choice in Phase II clinical trials [10].
Miltefosine is the last drug successfully introduced against VL. It is also the only drug that
has a good oral bioavailability. However, an increase in relapse rates has been reported in
India and Nepal, probably associated with low drug exposure [11, 12]. In addition, miltefosine
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is potentially embryotoxic and fetotoxic in experimental animals and thereby, its administra-
tion is not recommended in women during pregnancy [13].
For all these reasons, there is an unmet need to fill the antileishmanial drug discovery pipe-
line with safer drugs that display new mechanisms of action, likely allowing combination ther-
apy in order to prevent the emergence of resistant strains [14]. During this process, and once
compounds have shown high in vitro potency, selectivity, specificity, low toxicity and good
predictable pharmacokinetic/pharmacodynamic properties, a proof of concept that undoubt-
edly shows the in vivo efficacy of lead compounds, is required. Both mice and hamsters are
used as models of acute and chronic VL, respectively, during the evaluation of the proof of
concept [15, 16]. The most frequent technique to evaluate the infection course after drug treat-
ment has been microscopic counting of amastigotes in liver, spleen and bone marrow smears
stained with Giemsa dye. However, these are labour-intensive techniques that require specific
skill training and present low sensitivity when parasite burdens are low after treatment [17],
therefore, they are limited by tissue sampling biases, which require large animal cohorts.
In vivo real-time imaging combined with modified parasites expressing bioluminescent or
fluorescent reporters may accelerate the initial stage of drug discovery at the preclinical level.
Fluorescent reporters in the near infrared wavelength avoid interference with haemoglobin
and do not require the addition of substrate. However, and despite the number of near infra-
red proteins currently available [18, 19] further reporters with longer emission wavelengths
are still required in order to increase sensitivity. In this regard, red-shifted bioluminescent
reporters [20] are currently allowing the appraisal of different infections produced by Trypa-
nosomatids in vivo in real-time without the need to kill animals. This tool allows to run longi-
tudinal studies with a reduced number of animals since they are not sacrificed, and in addition
each animal is its own control, therefore the variability of experimental outcomes is limited
[21–25]. In summary, in vivo real-time imaging allows to develop the proof of concept in a
record time, accelerating the drug discovery process.
Nowadays, the mouse is used as acute preclinical model of VL, being liver the main affected
organ when experimental treatments are initiated at early times postinfection. On the contrary,
hamster is a more stringent and relevant model to recreate human VL [26, 27]. Generally
speaking, during chronic infections the persistence of pathogens yields a state of T cell dys-
function known as exhaustion that is characterized by the loss of effector functions, low recall
response and suboptimal T cell proliferation [28]. This is a hallmark feature shared by mice,
dogs and humans and it is associated with disease progression [29–31].
Here, we describe a chronic murine model of VL that combines in vivo real-time image
with stably modified strain expressing red-shifted luciferase (luc) aiming to track the presence
of parasites in target organs during a long-time course of infection that can be used for preclin-
ical drug-discovery. Miltefosine was used as proof of concept to assess the suitability of this
technique during drug discovery.
Methods
Ethics statement
The animal research described in this manuscript complies with Spanish Act (RD 53/2013)
and European Union Legislation (2010/63/UE). The protocols were approved by the Animal
Care Committee of the Centro de Biologı´a Molecular Severo Ochoa (CBMSO, Madrid, Spain),
project licence number JMJ/bb. Animals were maintained under specific pathogen-free condi-
tions in individually ventilated cages. They experienced a 12 h light/dark cycle and had access
to food and water ad libitum.
Chronic bioluminescent murine model for visceral leishmaniasis
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007133 February 14, 2019 3 / 15
Methods, mice and parasites
Seven to eight weeks-old female Balb/c mice were obtained from Janvier Labs (St Berthevin
Cedex, France) and housed in specific pathogen-free facilities in the P2-facility of CBMSO for
this study. L. infantum (strain MCAN/ES/96/BCN 150) promastigotes (previously obtained
from infected dogs) were a gift from J.M. Requena (CBMSO, Madrid, Spain). Parasites were
routinely cultured at 26 ˚C in M199 medium supplemented with 25 mM HEPES pH 6.9, 10
mM glutamine, 7.6 mM hemin, 0.1 mM adenosine, 0.01 mM folic acid, 1x RPMI 1640 vitamin
mix (Sigma-Aldrich), 10% (v/v) heat-inactivated fetal calf serum (FCS) and antibiotic cocktail
(50 U/ml penicillin, 50 μg/ml streptomycin).
Generation of red-shifted luc L. infantum strain
The 1647-bp PpyRE9h coding region was amplified by PCR from pGEX-6P-2 HCO RE9h vec-
tor, a kind gift from Dr. Bruce Branchini, (Department of Chemistry, Connecticut College,
CT, USA). The oligonucleotides used as primers (RBF919 and RBF920 in Table 1) introduced
NcoI-NotI as restriction sites for cloning into pLEXSY-PAC vector (Jena Bioscience) and XhoI
restriction site in the forward primer for cloning into pSK II vector. The 1647-bp PCR ampli-
fied fragment containing the PpyRE9h coding region was digested with XhoI and NotI and
cloned first into pSK II vector previously cut with the same restriction enzymes to yield
pSK-PpyRE9h plasmid. Then, this plasmid was cut with NcoI-NotI and the PpyRE9h ORF was
cloned into pLEXSY-PAC vector to yield the pLEXSY-PAC-PpyRE9h construct. Parasites
expressing red-shifted luc were obtained after electroporation of L. infantum BCN150 promas-
tigotes with the linear SwaI-targeting fragment obtained from pLEXSY-PAC-PpyRE9h vector.
Transfections were performed by electroporation (Gene Pulser X cell System, Biorad) using
10 μg of DNA fragments under the following conditions: 25 μF, 1500 v, 9 ms in 4 mm gap
cuvettes. Subsequent plating on semisolid media containing 200 μg/mL puromycin as selection
antibiotic, allowed the isolation of individual colonies that were subcultured in liquid media
under antibiotic pressure. The correct integration of each fragment into the 18S rRNA locus of
the resulting clones (PpyRE9h+L. infantum) was confirmed by PCR amplification analysis,
using appropriate primers (Table 1).
In vitro luciferase assay and microscopy
The Luciferase Assay System (Promega) was used to assess luc expression in PAC-isolated
clones from semisolid in vitro cultures. Briefly, 100×106 parasites were washed off with PBS
and then lysed with 1 ml of Cell Culture Lysis Reagent provided by the manufacturer. Cell
lysate was serially diluted in 96-well plate and then, ten microlitres of each cell lysate dilution
Table 1. Oligonucleotides used in this work.
Oligo No. Sequencea,b Purposedc Orientation
RBF919 ccgCTCGAGCCATGGCCACCATGGAGGACGCCAAGAACATCAA PpyRE9h Forward
RBF920 aaggaaaaaaGCGGCCGCTCAGATCTTGCCGCCCTTCTTGG PpyRE9h Reverse
RBF 630 CTTGTTTCAAGGACTTAGCCATG 50integration Forward
RBF 637 TATTCGTTGTCAGATGGCGCAC 50integration Reverse
RBF 644 CATGTGCAGCTCCTCCCTTTC 30integration Forward
RBF 645 CCTTGTTACGACTTTTGCTTC 30integration Reverse
aUnderlined sequence indicates restriction site.
bBold sequence indicates optimized translation initiation sequence.
cOrientation of primers: F, forward; R, reverse
https://doi.org/10.1371/journal.pntd.0007133.t001
Chronic bioluminescent murine model for visceral leishmaniasis
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007133 February 14, 2019 4 / 15
were mixed with 90 μL of luciferin substrate. Luminescence was measured immediately using
a Synergy HT microplate reader (BioTek).
In order to recover the infectivity of PpyRE9h+L. infantum strain after cloning, 108 metacyc-
lic promastigotes were inoculated intravenously (IV) in the tail vein. Mice were sacrificed 4
weeks later and spleens were used to recover infective amastigotes. Amastigotes were isolated
from the spleen by passing the tissue through a wire mesh. Then, splenocytes were disrupted by
passing sequentially through 27G1/2 and 30G1/2 needles. Finally, cell debris was retained by
passing successively through polycarbonate membrane filters with pore sizes of 8 μm, 5 μm and
3 μm (Isopore, Millipore). Released amastigotes (free of host cells), were washed twice with PBS
(4000 x g for 20 min at 4˚C) and counted by direct microscopy. To assess luciferase expression
in intracellular infections, phorbol 12-myristate 13-acetate (PMA)-differentiated THP1 human
monocytic leukemia cells, were grown on 8-well chambered coverslips (IBIDI) and incubated
with infective amastigotes recuperated from mice in a ratio of 1:10 for further 4 hours. Extracel-
lular parasites were removed by extensive washing with warm PBS and processed for immuno-
fluorescence analysis 5 days after infection. Briefly, coverslips were fixed with 2% (v/v)
paraformaldehyde in PBS and incubated with 0.1% (v/v) Triton X-100 in PBS for 10 min at
room temperature in order to permeabilize the cells. Slides were then probed with 1:1000 red
firefly luciferase polyclonal antibody (ThermoFisher); followed by 1:500 DyLight 633-conju-
gated goat anti-rabbit IgG secondary antibody for 30 min at room temperature. DNA was
labelled using 1 μM Hoechst 33342 before mounting with Vectashield mounting medium.
Images were acquired on a Zeiss LSM800 microscope with airyscan at 60X magnification.
In vivo mice infection with PpyRE9h+L. infantum parasites. Bio-
luminescent imaging (BLI)
Different infective doses of stationary phase PpyREh9+L. infantum promastigotes (ranging
from 5x104 to 5x108) were IV injected to 6–8 weeks-old female Balb/c mice. Every week ani-
mals were placed in a Charge-Coupled Device (CCD) IVIS 100 Xenogen system (Caliper Life
Science) for BLI analysis and images were acquired 10–20 min after intraperitoneal D-luciferin
injection (150 mg/kg). Briefly, the animals were lightly anesthetized with 2.5% isofluorane
(then reduced to 1.5%), before being placed on the camera. To standardize image capture and
in order to allow comparison between mice, the images presented in the figures correspond to
an acquisition time of 1 min duration, taken once luminescence plateaued.
To estimate the parasite burden in living mice, Regions Of Interest (ROIs) around liver and
spleen in ventral and lateral animals’ positions were drawn using Living Image v.4.3 to quan-
tify BLI expressed as radiance (p/s/cm2/sr). The detection threshold for in vivo imaging was
estimated using uninfected mice placed in different positions (ventral and lateral), using ROIs
of whole animals (n = 16).
At the end of some experiments, animals were euthanized and dissected, to confirm para-
site burden by more conventional methods. Briefly, spleens and livers were reimaged ex vivo
and used to quantify parasite load by Limit Dilution Assay (LDA). LDA was calculated as the
geometric mean of the titer obtained from quadruplicate cultures x reciprocal fraction of the
homogenized organ added to the first well. The titer was the reciprocal value of the last dilu-
tion in which parasites were observed [32].
Statistic analysis
Individual animal values were used as the unit of analysis of in vivo and ex vivo experiments.
Statistical differences between groups were evaluated using t-student test using SigmaPlot
v.14.0. Differences of P< 0.05 were considered significant.
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Results
Highly sensitive in vitro imaging of L infantum expressing red-shifted luc
PpyRE9h was stably integrated into the 18S rRNA promoter using pLEXSY vector (Fig 1A).
Correct integration of reporter gene into the resulting clones (PpyRE9h+L. infantum) was con-
firmed by PCR amplification analyses using the primers of Table 1 (Fig 1B). The PCR-con-
firmed clones were screened for luciferase activity and those having higher activity were
selected for in vivo experiments. Promastigote cultures of PpyRE9h+L.infantum grew at the
same rate as wild-type parasites (Fig 1C). There was a linear relationship between the luciferase
activity in vitro and the number of parasites independently of the parasite stage (logaritmic,
metacyclic or freshly isolated amastigotes) and independently of the instrument for measuring
(luminometer or IVIS camera). Fig 1D shows the relationship between luciferase activity and
the number of logaritmic promastigotes (PpyRE9h+L.infantum and wild-type strains). Cell
lysates from promastigotes were serially diluted into 96-well plate, D-luciferin was added and
luciferase activity was measured using a luminometer (103–106 cells range, r2 = 0.999), being
the detection limit of 103 promastigotes/well. The PCR-clone with the highest luciferase activ-
ity was selected for recovering infectivity through mouse (see Materials and Methods). Fig 1E
shows the outcomes using metacyclic promastigotes and free amastigotes in the IVIS camera.
In this experiment 6x106 parasites (metacyclic and amastigotes) were serially diluted in a
96-well plate, 100 μl D-luciferin were added and luciferase activity was measured in the IVIS
camera (4.68x104-6x106 cells range, r2 = 0.987 for metacyclic and r2 = 0.994 for amastigotes).
The detection limit was 9.37x104 metacyclic/well and 7.5x105 amastigotes/well. This suggests
that more amastigotes than metacyclic promastigotes are required for their detection by the
IVIS camera.
Spleen-isolated amastigotes were used to infect PMA differentiated THP-1 macrophages.
Four hours later the non-phagocytosed parasites were gently washed off with warm PBS and
left for further 96 h. The infection was stained using anti-firefly luciferase antibody and its
localization was confirmed to be cytosolic by confocal microscopy (Fig 1F).
Threshold sensitivity of bioluminescence PpyRE9h+L. infantum strain in
vivo
The infectivity of the selected clone was enhanced by passing through Balb/c mice that were
successively infected with 108 promastigotes by IV route until spleen weight increased up to
0.7–1 g (4–5 passages through mice). To establish the in vivo sensitivity of the PpyRE9h+L.
infantum strain, Balb/c mice were IV injected with different doses of infective metacyclic pro-
mastigotes (5x104-5x106) and photographed 1 h postinfection. At this time, the bioluminescent
signal was detected in the liver but only with the highest doses (5x105 and 5x106). Forty-eight
hours later when most promastigotes have transformed into amastigotes; BLI signal was only
detected from mice infected with 5x106 parasites (Fig 2A). The appraisal of the infection
showed that BLI signal in the liver peaked ~3 weeks post-infection (acute phase), then disap-
peared slowly from this organ and increased in the spleen (chronic phase) (Fig 2A). To esti-
mate the in vivo limit of detection with PpyRE9h+L. infantum parasites, we used BLI signal
expressed as radiance (p/s/cm2/sr). The limit of detection in vivo was estimated to be above
1x106 parasites at 48 h postinfection, when metacyclic parasites have transformed into intracel-
lular amastigotes (Fig 2B).
We were interested in developing a chronic model of infection to use as proof of concept
for well-established infections in spleen and bone marrow. In order to evaluate the stability of
bioluminescent signal through time in chronic infections, 5x108 metacyclic promastigotes
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Fig 1. Generation of a L. infantum stably expressing PpyRE9h red-shifted luciferase. A) Scheme of the structure of the
18S rRNA locus on wild type and planned integration of PpyRE9h gene. Key: utr1: non-translated region of aprt gene; utr2:
1.4 kb intergenic region from cam operon; and utr3: UTR of dhfr-ts gene; PAC; puromycin resistance cassette. B) PCR
confirmation of successful integration of the reporter cassette. Primers 630/637 and 644/645 together confirm the correct
integration of the reporter cassette into genome sequences. (see Table 1 for sequences). C) Growth rate of wild-type (black
circle) and stably-modified promastigotes PpyRE9h+L.infantum (white circle). Parasites were counted using a Coulter
counter. D) In vitro luciferase activity assay of diluted lysates from wild-type (WT) and PpyRE9h+L.infantum
promastigotes after PCR confirmation. E) Minimal metacyclic promastigote and infective amastigote number detectable by
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were IV injected and animals were photographed in ventral and lateral positions from 5 to 16
weeks post-infection. The spleen infection was detected independently of the animal positions.
BLI signal was increasing from week 5 to reach the maximum radiance 12 weeks after infection
(Fig 2C). Moreover, bone marrow radiance was detected only in ventral images from 8 to 16
weeks, and the bioluminescent signal was increasing during this time (Fig 2C).
To establish a correlation between BLI signal detected in vivo and the parasite burden in
liver and spleen, mice (n = 12, one animal died before the end of the experiment) were infected
with parasite dose ranging from 5x106-5x108. Nine weeks postinfection, animals were imaged
and the luminescence was recorded in vivo in the regions of interest (ROI) previously drawn
around the spleen and liver. Animals were euthanized and the liver and spleen processed to
determine parasite burden. Both organs showed a good correlation with the in vivo recorded
BLI signal (Fig 2D and 2E).
Validation of the luciferase model with miltefosine
PpyRE9h+L. infantum infected mice were treated with miltefosine as a proof-of-concept to val-
idate this model in a long-term follow-up infection.
Mice (n = 30) were IV infected with 5x108 metacyclic promastigotes and imaged for BLI
after 3, 7, 12 and 14 wpi confirming that infection was established (Fig 3A). Animals were
divided in groups and half of them were treated with miltefosine 40 mg/kg/day for 5 days by
oral gavage. Once miltefosine treatment was ended, animals were imaged and sacrificed at dif-
ferent times (48 h, 1 and 6 weeks post-treatment that corresponded to 15, 16 and 21 wpi). Fig
3B (top panel) shows that BLI signal in whole animals was almost undetectable after miltefo-
sine treatment (48 h post-treatment) in a chronic infection, and that the BLI reduction per-
sisted for 6 weeks after the end of the treatment. Quantification of the BLI signal revealed that
radiance in untreated animals (3x105 p/s/cm2/sr) decreased significantly to 2.32x104 and
1.61x103; one and six weeks, respectively after the end of the treatment, reaching BLI values
similar to non-infected animals (Fig 3B; bottom panel P<0.05).
Animals were sacrificed at different times after the end of treatment (48h, 1 week and
6 weeks posttreatment) and the organs (spleen and liver) were photographed after injecting D-
luciferin ex vivo (Fig 3C). There was a significant marked reduction in the weight of the spleen,
which reached values similar to those of the uninfected animals at 6 weeks after the end of the
treatment (Fig 3D P<0.001). Ex vivo bioluminescent values recorded from treated and
untreated animals over the time were plotted (Fig 3E) confirming the BLI reduction seen in
vivo. The BLI decrease was significant at all analysed times in both organs (P<0.001) with the
exception of the liver at 48h posttreatment that was not significant and liver at 6wpi (P<0.01).
Both organs showed logarithmic reduction of BLI from the end of the treatment to 6 weeks
later. Ex vivo parasite burden was estimated using limiting dilution assay confirming parasite
load reductions of 98%, 99,9%, and 99,9%, at 48h, 1 week and 6 weeks postinfection (Fig 3F).
Discussion
The introduction of new medicines against VL from the initial concept to public release is a
time-consuming and expensive process. Moreover, the clinical recurrences after treatment
the IVIS camera. Parasites were loaded in 96-well plates, D-luciferin added and the BLI signal was detected in the IVIS
camera. Grey lines indicate detection thresholds determined as the mean (solid line) and mean +2SDs (dashed line) of
background luminescence of wells with PBS free-parasites. F) Microscopic image of intracellular PpyRE9h+L.infantum
amastigotes infecting PMA-differentiated THP-1 cell line. Bioluminescent amastigotes stained with anti-luciferase IgG
(αLuc, red) and Hoechst 33342 DNA stain (H33342, cyan).
https://doi.org/10.1371/journal.pntd.0007133.g001
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Fig 2. Evaluation of L. infantum infection in Balb/c mice by in vivo BLI. A) Representative images of Balb/c mice infected via
IV with 5x104—5x106 metacyclic PpyRE9h luciferase-expressing promastigotes. Pseudocolour heat-maps indicate intensity of
bioluminescence from low (blue) to high (red). All images use the same log10 scale heat-map, minimum and maximum radiance
values are indicated. Animals at 9 and 12 weeks postinfection are in lateral position where most of the BLI signal was detected B)
Quantification of whole animal total bioluminescence for mice in the experiment illustrated in A) at 48 h postinfection. C) Time-
appraisal of Balb/c mice after IV injection with 5x108 red-shifted bioluminescent parasites (PpyRE9h+L.infantum) in ventral and
lateral positions. Quantification of ventral and lateral bioluminescence from the experiment represented by the images in C). D-E)
Correlation between in vivo bioluminescence values and parasite burdens in the liver and the spleen. Bioluminescence was
Chronic bioluminescent murine model for visceral leishmaniasis
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failure and the emergence of resistances are worsened by the shortage of new clinical entities
and the long period needed to release a new medicine [33]. To bridge the gap between early
drug identification and in vivo preclinical studies, new bioimaging tools have recently been
introduced to accelerate the drug discovery process while drastically reducing the number of
animals used.
To develop robust preclinical in vivo platforms, several aspects related to the genetic modifi-
cations introduced in the pathogen and the suitability of the animal model should be addressed
before their validation with a proof of concept [34, 35]. In such a way, we present here the gen-
eration of the strain PpyRE9h+L. infantum and its utility to quantify the parasite load in vivo in
infected mice in real time. As the virulence of the modified strain can be lost after genetic
manipulation and passage in culture, as soon as the correct integration of the construct was
confirmed, the selected clone was passed through mice to recover its infectivity [36, 37, 38].
Once D-luciferin was administered, the light detected by CCD camera and transformed to
pseudocolor images, enabled parasite traceability in the whole body and the estimation of par-
asite burden in a murine model of chronic VL, reducing the number of animals to be analysed
in longitudinal studies. During in vivo infections amastigotes enter into a semi-quiescent phys-
iological stage in which major energetic processes are specifically repressed [39], explaining
the differences in light emission between metacyclic promastigotes and freshly isolated amasti-
gotes. However, our results show that parasites emitted light enough to provide accurate and
rapid radiance that allow the appraisal up to 21 wpi. In this study, light could be detected in
Balb/c mice in the liver during the acute phase of infection and later in the spleen and bone
marrow during the chronic phase, allowing a continuous and long-term follow-up of the infec-
tion. Under these conditions, light detected in vivo–that corresponded to ROIs drawn around
liver and spleen—correlated well with parasite burden calculated from LDA, which it would
allow to estimate the parasite burden without the sacrifice of animals.
The location of parasites (peripheral or deeper tissues) within the mammalian host has
been pointed as a key factor affecting the limit of parasite detection in vivo [40]. The light emit-
ted by freshly isolated amastigotes from splenic lesions in our system showed a detection
threshold similar to the previously reported by other authors [22].
In experimental VL, the hamster is considered the best experimental model since it repro-
duces many clinicopathological features of the human disease and can be fatal in the absence
of treatment [41]. High-dose murine models of VL develop hallmarks of progressive human,
primate, and canine disease with loss of gp38 stromal cells [42], remodelling of splenic mar-
ginal zone region [43], altered migration of DCs [42] and loss of follicular germinal centers
[44]. For this reason, Balb/c mice have been proposed as an adequate model of chronic VL
[45–46]. In addition, during chronic infections the persistence of pathogens yields a state of T
cell dysfunction known as exhaustion that is characterized by the loss of effector functions, low
recall response and suboptimal T cell proliferation [28]. In VL, this stage of T cell exhaustion is
associated with disease progression in mouse, dogs and human infections [29–31]. For this
reason and in order to have a murine BLI model of chronic VL, the inoculum size was
increased to 5x108 metacyclic parasites per mouse.
In previous studies we have used the same L. infantum/Balb/c model showing hallmarks of
progressive infection [47]. PpyRE9h+L. infantum strain allowed a continuous monitoring of
parasite load from the beginning of the infection up to animal’s sacrifice, detecting both acute
measured in vivo in ROIs around liver and spleen and parasite numbers were quantified by limiting dilution assay after animals
were sacrificed. Grey lines indicate detection thresholds determined as the mean (solid line) and mean +2SDs (dashed line) of
background luminescence of control uninfected animals.
https://doi.org/10.1371/journal.pntd.0007133.g002
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Fig 3. Chronic L. infantum infection in space and time. A) Representative ventral and lateral view images of Balb/c mice taken at
sequential time points over the course of 14 weeks after IV infection with 5 x 108 PpyRE9h luciferase-expressing L.infantum
metacyclic promastigotes (representative of n = 30). In the images corresponding to 14 wpi only lateral views are shown because
most of BLI signal was detected in this position. Heat-maps are on log10 scales indicate intensity of bioluminescence from low
(blue) to high (red); the minimum and maximum radiances for the pseudocolour scale are indicated. B) Animals (n = 15) were
treated with 40 mg/kg/d miltefosine via oral for 5 days. Treated and untreated animals were photographed, sacrificed and the
spleen and liver imaged at 48 h, 1 week and 6 weeks after the end of miltefosine treatment (15, 16 and 21 wpi). Quantification of
lateral bioluminescence for mice shown in B. The red asterisk indicates the start of miltefosine treatment. In vivo radiance from
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and chronic infections. In view of these results, PpyRE9h+L. infantum constitutes an ideal tool
for the appraisal of drug efficacy in in vivo preclinical models.
The assay was validated by the treatment with miltefosine, starting 14 weeks post-infection
and extended for long-term appraisal (6 weeks after drug withdrawal). In rodents miltefosine
is known to produce significant parasite burden reduction (90–99% depending on parasite
strain) in liver and spleen, along with no-sterile cure (when the treatment is initiated at 7–21
days postinfection [48–50]. These no-sterile curative results were confirmed later in hamster
models of chronic VL treated with high-dose miltefosine (20 mg/kg/10 days), started 40 days
post infection, although it resulted in 100% survival measured 20 wpi [23]. In our study, both
radiance and parasite burden values dropped immediately after the end of treatment and they
remained decreasing during the long-term follow up, although sterile cure was never achieved.
A possible disease recurrence due to incomplete parasite suppression was expected. However,
and despite the long-term follow up, much beyond the half-life of miltefosine [51], no recur-
rence was seen.
Several studies with AmBisome and stibogluconate in mice have shown that the infection
status influenced treatment outcome, so that treatments were less effective in the chronic
infection model than in acute infection models [52, 53]. The changes that occur in liver and
spleen structure and function during early and late stages on infection might be the cause [46].
The mouse model proposed in this work would provide accurate information about potential
drugs and their efficacy on the later stages of infection when it has been described that the effi-
cacy of several drugs might be more compromised.
In conclusion, the gold standard methods used to evaluate the efficacy of antileishmanial
drugs based on LDA or microscopic examination are laborious and time-consuming, have
intrinsic variability, require intensive use of animals and cannot be monitored in real time.
However, novel in vivo bioimaging models based on bioluminescent L. infantum parasites are
highly sensitive, easily traceable, and yet provide statistically valuable outcomes with the use of
far fewer animals than traditional methods. This technology is reproducible; less expensive
because it reduces the number of animals needed, it is barely distressing for animals and can
be easily adapted to different experimental models being thereby suitable to accelerate drug
development.
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